Capio Biosciences

Capio Biosciences is a biotechnology company focused on improving cancer patient outcomes through advanced oncology diagnostics. The company operates in the healthcare and biotech market, specializing in the capture and analysis of Circulating Tumor Cells (CTCs) from whole blood. These CTCs are robust biomarkers that can help oncologists make more informed cancer treatment decisions. Capio Biosciences serves medical professionals, researchers, and healthcare institutions by providing a highly sensitive diagnostic platform known as CapioCyte. This platform boasts a sensitivity up to 100 times greater than currently available technologies, making it a valuable tool for both cancer research and potential clinical applications.

Capio Biosciences generates revenue through the sale of its diagnostic platforms and related services. The business model is centered around providing cutting-edge technology that offers enhanced sensitivity and accuracy in detecting CTCs, thereby aiding in early cancer detection and treatment planning.

Keywords: oncology diagnostics, Circulating Tumor Cells, cancer research, CapioCyte, biomarkers, healthcare, biotech, clinical applications, sensitivity, cancer treatment.